Clinical trials: Hep A
Autoimmune Liver Disease, Autoimmune Hepatitis
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents.
- Conditions
- Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
- Trial name
- NCT03178630
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Severe Acute Exacerbation of Chronic Hepatitis B
Efficacy of Short-term Immunosuppressive Therapy and Anti-allergenic Therapy in Severe Acute Exacerbation of Chronic Hepatitis B
The investigators will investigate the clinicopathological features of chronic hepatitis B patients with severe exacerbation selected by uniform criteria, and treated with early introduction or reintroduction of corticosteroids…
- Trial name
- NCT01627236
- Testing
- methylprednisolone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C, Hepatitis C, Chronic
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
This study has two parts. Part A will assess the safety, tolerability and pharmacokinetics (PK) of AT-777 in healthy subjects. Part B will assess the safety, antiviral activity/efficacy and PK of AT-777 in combination with AT-527…
- Conditions
- Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C, Hepatitis C Virus Infection
- Trial name
- NCT04309734
- Testing
- AT-777, AT-527
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C Virus
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
- Trial name
- MAGNITUDE (NCT01741545)
- Testing
- Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 71 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, Decompensated Cirrhosis
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
The primary objectives of this study are to assess the safety and the SVR12 rate of ombitasvir/paritaprevir/ritonavir and dasabuvir with RBV in GT1-infected participants with decompensated cirrhosis.
- Conditions
- Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
- Trial name
- TURQUOISE-CPB (NCT02219477)
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 36 people
- Sponsor
- AbbVie
Hepatitis C
The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients
This is an open label, dose ranging, phase1a/1b clinical trial to study the safety, Pharmacokinetics and Pharmacodynamics of Peglamda 60, 120, 180 and 240 mcg in healthy volunteers and antiviral activity of once weekly Peglamda…
- Trial name
- NCT02063607
- Testing
- Peginterferon lambda
- Where
- Vietnam
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Viral Hepatitis C
Re-linkage to Care of Patients With Hepatitis C
The purpose of this study is to identify patients with chronic hepatitis C virus (HCV) who were lost of follow up and relinkage them to hepatitis C care
- Trial name
- NCT04470271
- Testing
- Patients with hepatitis C lost follow up
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- Austral University, Argentina
Liver Cirrhosis, Chronic Hepatitis B
Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation
An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.
- Trial name
- LT (NCT02125071)
- Testing
- Blood Sample Collection
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Dong-Gu Kim
Hepatitis C Virus
Hepatitis C Virus and the Humoral Immune System
The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection.
- Trial name
- NCT00219999
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Hepatitis C
SOF/VEL±RBV: Efficacy and Safety in GT 3 and 6 HCV Patients
150 GT3 or GT6 CHC patients with or without compensated cirrhosis will be recruited from five centers in China including G3a 50, G3b 50, G6 50 respectively.
- Trial name
- NCT04948801
- Testing
- Epclusa (sofosbuvir and velpatasvir)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis C
CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects
To explore the effect on early viral kinetics and viral load, and to determine safety, tolerability and anti-viral response for the plasmid DNA vaccine CHRONVAC-C administered i.m.
- Trial name
- NCT01335711
- Testing
- ChronVac-C + SOC, SOC
- Where
- 2 sites in Sweden
- Volunteers
- 32 people
- Sponsor
- ChronTech Pharma AB
Chronic Hepatitis C, Hepatitis C
Study of AT-527 in Healthy and HCV-Infected Subjects
This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV).
- Conditions
- Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT03219957
- Testing
- AT-527
- Where
- 2 sites in Belgium, Moldova
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C Virus Infection
Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection
This study will have 2 parts: Pharmacokinetics (PK) Lead-in Phase and the Treatment Phase. The primary objective of the PK Lead-in Phase is to evaluate the steady state PK and confirm the dose of sofosbuvir/velpatasvir (SOF/VEL)…
- Trial name
- NCT03022981
- Testing
- SOF/VEL
- Where
- 27 sites in United States, Belgium and 2 more
- Volunteers
- 216 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
The purpose of this protocol is to obtain pharmacodynamic and pharmacokinetic data on ABI-H0731 and to provide the opportunity for preliminary evaluation of combination therapy of ABI-H0731 with currently approved antiviral…
- Trial name
- NCT03109730
- Testing
- ABI-H0731, Entecavir, Tenofovir Disoproxil Fumarate
- Where
- 14 sites in Australia, Hong Kong and 3 more
- Volunteers
- 38 people
- Sponsor
- Assembly Biosciences
Chronic Hepatitis C
The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- REACH (NCT02582671)
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Volunteers
- 101 people
- Sponsor
- AbbVie
Lung Transplant Infection, Hepatitis C
Lung Transplant HCV, Pilot Study
In this study HCV negative recipients will be transplanted with HCV positive lungs. Investigators will attempt to decrease infectivity rates by performing Normothermic Ex vivo Lung Perfusion (EVLP), which is an approved method of…
- Trial name
- NCT03112044
- Testing
- Sofosbuvir-velpatasvir (400 mg/100 mg), Ex Vivo Lung Perfusion (EVLP)
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- University Health Network, Toronto
Hepatitis C, Chronic
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
This randomized, cross-over, open label study will compare the tolerability and handling of application of peginterferon alfa-2a [Pegasys] by autoinjector versus pre-filled syringe in patients with chronic hepatitis C, either on…
- Trial name
- NCT01087944
- Testing
- Autoinjector, Pre-filled syringe
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Vaccination; Complications, Reaction, Serum
Dose of Hepatitis B Vaccines in Non/Low-response Populations
An interventional study will be performed in subjects aged 1-65 years old to evaluate effects of different doses of hepatitis B vaccines in low or non-response population.
- Trial name
- NCT01564134
- Testing
- hepatitis B vaccine
- Where
- 2 sites in China
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- Wu Jiang
Liver Pathology
Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C
Regardless of its etiology (chronic hepatitis B or C, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue.
- Trial name
- DEP-CB (NCT06755632)
- Testing
- TROD (rapid diagnostic orientation test) and FibroScan®
- Where
- 2 sites in France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Hepatitis B
Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients
This Phase 1 trial will assess the dose-related safety and PK profile of different doses of NVR 3-778, first in healthy volunteer subjects (part I) and subsequently in patients with chronic hepatitis B (part II).
- Trial name
- NCT02112799
- Testing
- NVR 3-778, Pegasys
- Where
- 2 sites in New Zealand
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Novira Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.